AbbVie Inc.
ABBV · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $56 | $54 | $58 | $56 |
| % Growth | 3.7% | -6.4% | 3.3% | – |
| Cost of Goods Sold | $17 | $20 | $17 | $17 |
| Gross Profit | $39 | $34 | $41 | $39 |
| % Margin | 70% | 62.4% | 70% | 69% |
| R&D Expenses | $13 | $8 | $7 | $8 |
| G&A Expenses | $11 | $11 | $13 | $10 |
| SG&A Expenses | $13 | $13 | $15 | $12 |
| Sales & Mktg Exp. | $2 | $2 | $2 | $2 |
| Other Operating Expenses | $4 | $1 | $1 | $0 |
| Operating Expenses | $30 | $21 | $23 | $21 |
| Operating Income | $9 | $13 | $18 | $18 |
| % Margin | 16.2% | 23.5% | 31.2% | 31.9% |
| Other Income/Exp. Net | -$5 | -$7 | -$5 | -$5 |
| Pre-Tax Income | $4 | $6 | $13 | $13 |
| Tax Expense | -$1 | $1 | $2 | $1 |
| Net Income | $4 | $5 | $12 | $12 |
| % Margin | 7.6% | 9% | 20.4% | 20.5% |
| EPS | 2.4 | 2.73 | 6.65 | 6.48 |
| % Growth | -12.1% | -58.9% | 2.6% | – |
| EPS Diluted | 2.39 | 2.72 | 6.63 | 6.45 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $3 | $2 | $2 | $2 |
| Depreciation & Amortization | $8 | $9 | $8 | $9 |
| EBITDA | $15 | $17 | $24 | $24 |
| % Margin | 26.5% | 31.6% | 41.6% | 42.6% |